Table 1.
Patient characteristics
| Variables | Total (n = 69) | Central (n = 28) | Peripheral (n = 41) | p-value |
|---|---|---|---|---|
| Age | ||||
| Mean ± SD | 73.9 ± 8.2 | 76.0 ± 8.3 | 72.4 ± 7.9 | 0.036a |
| Median | 75 | 78 | 72 | |
| Gender | ||||
| Male | 57 | 23 | 34 | 1.00 |
| Female | 12 | 5 | 7 | |
| Smoking index | ||||
| Mean ± SD | 1297 ± 1803 | 1675 ± 2735 | 1039 ± 558 | 0.076 |
| Median | 960 | 1010 | 960 | |
| ECOG PS | ||||
| 0 or 1 | 62 | 25 | 37 | 1.00 |
| 2 or 3 | 7 | 3 | 4 | |
| LDH [normal: 129–241 (IU/l)] | ||||
| Mean ± SD | 247.6 ± 95.8 | 273 ± 131.3 | 230.3 ± 56.4 | 0.034a |
| Median | 223 | 250.5 | 214 | |
| Tumour markers | ||||
| NSE [normal <12 (ng ml−1)] | ||||
| Mean ± SD | 50.4 ± 74.1 | 74.9 ± 100.8 | 33.3 ± 40.9 | 0.11 |
| Median | 22.4 | 31.7 | 20.9 | |
| ProGRP [normal <70 pg ml−1)] | ||||
| Mean ± SD | 996 ± 3118 | 1630 ± 4554 | 562 ± 435 | 0.082 |
| Median | 135 | 407 | 122 | |
| CYFRA [normal <2.2 ng ml−1)] | ||||
| Mean ± SD | 3.59 ± 2.55 | 3.06 ± 1.50 | 3.94 ± 3.02 | 0.92 |
| Median | 3 | 2.7 | 3.05 | |
| CEA [normal <5 (ng ml−1)] | ||||
| Mean ± SD | 21.7 ± 70.3 | 30.6 ± 94.8 | 15.7 ± 47.4 | 0.2 |
| Median | 4.5 | 5.4 | 4.5 | |
| Stage | ||||
| Limited disease | 38 | 14 | 24 | 0.62 |
| Extensive disease | 31 | 14 | 17 | |
| Therapy | ||||
| Chemoradiotherapy | 27 | 14 | 13 | 0.14 |
| Chemotherapy | 42 | 14 | 28 | |
| P-SUVmax [g ml−1] | ||||
| Mean ± SD | 9.86 ± 5.46 | 11.74 ± 5.77 | 8.61 ± 4.93 | 0.0098a |
| Median | 9.75 | 10.6 | 9.3 | |
| H-SUVmax [g ml−1] | ||||
| Mean ± SD | 11.69 ± 4.63 | 12.21 ± 5.52 | 11.32 ± 3.95 | 0.22 |
| Median | 11.6 | 11.65 | 11.5 | |
| WB-MTV [cm3] | ||||
| Mean ± SD | 72.6 ± 82.1 | 100.6 ± 93.6 | 53.4 ± 68.1 | 0.018a |
| Median | 43.9 | 74.0 | 38.3 | |
| WB-TLG [g] | ||||
| Mean ± SD | 568.6 ± 771.2 | 823.6 ± 915.6 | 394.5 ± 607.2 | 0.022a |
| Median | 336.1 | 607.6 | 226.3 | |
CEA, carcinoembryonic antigen; CYFRA, cytokeratin 19 fragment; ECOG, Eastern Cooperative Oncology Group; H-SUVmax, maximum standardized uptake value of the highest lesion of the disease; IU, international unit; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; ProGRP, pro-gastrin-releasing peptide; PS, performance status; P-SUVmax, maximum standardized uptake value of the primary tumour lesion; SD, standard deviation; WB-MTV, whole-body metabolic tumour volume; WB-TLG, whole-body total lesion glycolysis.
The paired t-test was used for the evaluation of age, smoking index, LDH, tumour markers, maximum of standardized uptake value, MTV and TLG. Fisher's exact test was used for the evaluation of sex, performance status, stage and therapy.
p < 0.05.